Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
The First Clinical Medicine College, Lanzhou University, Lanzhou, 730000, China.
Drugs Aging. 2023 Oct;40(10):881-893. doi: 10.1007/s40266-023-01053-1. Epub 2023 Aug 18.
Managing hypertension in frail older patients is challenging. Several institutions and organizations have published up-to-date hypertension guidelines suggesting frailty screening among older hypertensive patients, with new recommendations for blood pressure-lowering treatment among the frail population. However, the quality of current hypertension guidelines and the consistency of antihypertension treatment recommendations for frail older patients and their supporting evidence remain unknown.
In this review, we aimed to systematically collect guidelines with antihypertension treatment recommendations for frail older patients, examine and compare these recommendations, and critically assess reporting and methodology quality of these guidelines.
A literature search was conducted on two databases and three major websites of guideline development organizations. The AGREE instrument and RIGHT checklist were used to evaluate the methodology and reporting quality of the guidelines, respectively. The consistency of recommendations within the guidelines were compared using descriptive analysis.
We identified 13 hypertension guidelines. The overall methodology quality scores (range 23.35-79.07%) and reporting rates (range 10/35-29/35) varied among these guidelines. Four guidelines provided an explicit definition of frailty. Considering treatment tolerability or increased likelihood of adverse effects while using pharmacotherapy in frail older patients was mentioned in all guidelines. Ten guidelines recommended adjusting blood pressure targets or specific pharmacotherapy programs. Four guidelines recommended using clinical judgment when prescribing. However, the specific recommendations lacked clarity and unity without sufficient evidence.
There were considerable variations in methodology and reporting quality across the 13 included hypertension guidelines. Furthermore, the depth and breadth of antihypertension treatment recommendations for frail older patients were varied and inconsistent. Further trials exploring optimal treatment are urgently required to promote the development of specific guidelines for managing frail older hypertensive patients.
管理虚弱的老年高血压患者具有挑战性。一些机构和组织发布了最新的高血压指南,建议对老年高血压患者进行虚弱筛查,并对虚弱人群的降压治疗提出了新的建议。然而,目前高血压指南的质量以及针对虚弱老年患者的降压治疗建议的一致性及其支持证据尚不清楚。
在本综述中,我们旨在系统地收集针对虚弱老年患者的降压治疗建议的指南,检查和比较这些建议,并批判性地评估这些指南的报告和方法学质量。
我们在两个数据库和三个主要指南制定组织的网站上进行了文献检索。使用 AGREE 工具和 RIGHT 清单分别评估指南的方法学和报告质量。使用描述性分析比较指南中建议的一致性。
我们确定了 13 项高血压指南。这些指南的总体方法学质量评分(范围 23.35-79.07%)和报告率(范围 10/35-29/35)存在差异。有 4 项指南明确定义了虚弱。所有指南都提到了在虚弱的老年患者中使用药物治疗时要考虑治疗耐受性或增加不良反应的可能性。有 10 项指南建议调整血压目标或特定的药物治疗方案。有 4 项指南建议在开处方时使用临床判断。然而,具体建议缺乏清晰度和一致性,没有足够的证据支持。
13 项纳入的高血压指南在方法学和报告质量方面存在相当大的差异。此外,针对虚弱老年高血压患者的降压治疗建议的深度和广度也存在差异且不一致。迫切需要进一步的试验来探索最佳治疗方法,以促进针对管理虚弱老年高血压患者的具体指南的发展。